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ABSTRACT
Objective To evaluate the effects of drug interventions 
that may modify the progression of chronic kidney disease 
(CKD) in adults with CKD stages 3 and 4.
Design Systematic review and meta-analysis.
Methods Searching MEDLINE, EMBASE, Database of 
Abstracts of Reviews of Effects, Cochrane Central Register of 
Controlled Trials, Cochrane Database of Systematic Reviews, 
International Clinical Trials Registry Platform, Health 
Technology Assessment, Science Citation Index, Social 
Sciences Citation Index, Conference Proceedings Citation 
Index and Clinical Trials Register, from March 1999 to July 
2018, we identified randomised controlled trials (RCTs) of 
drugs for hypertension, lipid modification, glycaemic control 
and sodium bicarbonate, compared with placebo, no drug 
or a drug from another class, in ≥40 adults with CKD stages 
3 and/or 4, with at least 2 years of follow-up and reporting 
renal function (primary outcome), proteinuria, adverse 
events, maintenance dialysis, transplantation, cardiovascular 
events, cardiovascular mortality or all-cause mortality. Two 
reviewers independently screened citations and extracted 
data. For continuous outcomes, we used the ratio of means 
(ROM) at the end of the trial in random-effects meta-
analyses. We assessed methodological quality with the 
Cochrane Risk of Bias Tool and confidence in the evidence 
using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) framework.
Results We included 35 RCTs and over 51 000 patients. 
Data were limited, and heterogeneity varied. Final renal 
function (estimated glomerular filtration rate) was 6% 
higher in those taking glycaemic control drugs (ROM 1.06, 
95% CI 1.02 to 1.10, I2=0%, low GRADE confidence) and 
4% higher in those taking lipid-modifying drugs (ROM 
1.04, 95% CI 1.00 to 1.08, I2=88%, very low GRADE 
confidence). For RCTs of antihypertensive drugs, there 
were no significant differences in renal function. Treatment 
with lipid-modifying drugs led to a 36% reduction in 
cardiovascular disease and 26% reduction in all-cause 
mortality.
Conclusions Glycaemic control and lipid-modifying drugs 
may slow the progression of CKD, but we found no pooled 
evidence of benefit nor harm from antihypertensive drugs. 
However, given the data limitations, further research is 
needed to confirm these findings.
PROSPERO registration number CRD42015017501.
InTRODuCTIOn
Chronic kidney disease (CKD) is a long-term 
loss of renal function and is a global health 
problem, with an estimated prevalence of 
11%–13%.1 CKD is an independent risk factor 
for cardiovascular disease,2 and people with 
mild-to-moderate CKD are at increased risk 
of mortality and progression to renal failure.3
Historically, CKD was categorised by its 
cause, which was predominantly diabetes, 
Strengths and limitations of this study
 ► By focusing on patients with chronic kidney disease 
(CKD) stages 3 and 4, we provide a primary care 
perspective on the management of CKD.
 ► We completed an extensive and comprehensive 
search including common drug mis-spellings, with 
no restriction on language or publication type.
 ► Generalisability of our findings is limited by the 
paucity of trials, high statistical heterogeneity, high 
clinical heterogeneity, in terms of comorbidities and 
by the effect of drugs on CKD being secondary in all 
the studies.
 ► Lack of data restricted our ability to explore the 
baseline characteristics of studies, the effects of 
drugs, and the link between treatment effect and 
drug dose, and assess the potential for publication 
bias.
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hypertension, glomerulonephritis or polycystic kidney 
disease. Treatment could be recommended, but often 
opportunities were missed for early detection of the 
disease or prevention of clinical complications and 
further deterioration. The National Kidney Founda-
tion addressed this challenge by developing a five-stage 
classification system based on the glomerular filtration 
rate (GFR) (online supplementary material),4 which 
was subsequently modified to take into account degrees 
of proteinuria (online supplementary material).5 A UK 
audit in 2012 estimated that 90% of cases of CKD are at 
stage 3, and of these 84% are at stage 3a (estimated GFR 
(eGFR) 45–59 mL/min/1.732).6
Patients with CKD who are managed in primary care 
include those in stages 1 and 2, with an emphasis on 
lifestyle and diet changes. Patients in stages 3 and 4 may 
be managed either in primary care or shared care with 
specialist nephrology services, with a greater use of medi-
cation, primarily for associated long-term conditions, 
such as diabetes and hypertension. Both published data 
for Oxfordshire7 and unpublished national data from 
our group show that some patients with CKD stage 4 have 
their renal function monitored in primary care.
Four different classes of drugs may modify CKD progres-
sion: antihypertensives,8 lipid-modifying drugs,9 glycaemic 
control medications in patients with diabetes10 and 
sodium bicarbonate.11–13 Sodium bicarbonate addresses 
metabolic acidosis, a prevalent complication in moderate 
and late-stage CKD, and may offer a simple and low-cost 
treatment to slow CKD progression. The effects of drugs 
on CKD are secondary, as these drugs are primarily used 
to treat hypertension, hypercholesterolaemia or diabetes.
Systematic reviews have been compiled to summarise 
the effects of drug interventions on the rate of CKD 
progression.9 10 14–16 However, while two have reported 
results based on eGFR, none has reported results with 
reference to CKD staging. Furthermore, no systematic 
review has compared the effects of different drug classes.
Our objective was to carry out a systematic review and 
meta-analysis of randomised controlled trials (RCTs) to 
examine and compare the effects on the progression of 
CKD of the four classes of drugs, focusing on patients 
who can be managed in primary care or shared care with 
specialist nephrology services.
METhODS
Our systematic review protocol was registered with PROS-
PERO (International Prospective Register of Systematic 
Reviews) and reported in line with the recommenda-
tions from the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses statement.17
Search strategy
The search strategy was designed by an information 
specialist (NR) with advice from clinicians including 
nephrologists. Medical Subject Headings (MeSH) 
terms included terms for population, study design and 
intervention drugs (randomised control trials, chronic 
kidney, renal, drug classes and specific drug names, 
including common mis-spellings). Our included drug list 
is shown in the online supplementary material.
Searches were conducted in Ovid MEDLINE (online 
supplementary material), Cochrane Central Register 
of Controlled Trials, Cochrane Database of Systematic 
Reviews, Database of Abstracts of Reviews of Effects, 
EMBASE, Health Technology Assessment, Science Cita-
tion Index, Social Sciences Citation Index, Conference 
Proceedings Citation Index, Clinical Trials Register, and 
the WHO International Clinical Trials Registry Platform 
to 6 July 2018 to identify relevant studies, regardless 
of their publication type. No language restriction was 
applied. All publications from March 1999 onwards were 
considered, to align with the publication of the first equa-
tion to calculate eGFR, which had led to the introduction 
of CKD staging.18 Reference lists were also examined.
Study selection
Two reviewers (KST, JM, NP and SF; in pairs) reviewed 
the title and abstract of each reference and identified 
potentially relevant references. Considering the full texts 
of these studies, two reviewers independently selected 
studies to be included in the review using predetermined 
inclusion criteria. Disagreements about study inclusion 
were resolved by a third reviewer.
The following were our study inclusion criteria:
1. RCTs of drugs that may modify the progression of 
CKD: antihypertensives, lipid-modifying drugs, glycae-
mic control drugs and sodium bicarbonate.
2. Control arms were either given a placebo drug, no 
drug intervention or a comparator drug from one of 
the three other classes.
3. Adult participants.
4. Patients with stage 3 and/or stage 4 CKD. Studies ad-
ditionally including patients with stage 1 and/or stage 
2 CKD were also included to increase the number of 
potential studies, but we would expect the treatment 
effect to be overestimated in these studies, as patients 
with stage 1 and 2 CKD would respond better to treat-
ment.
5. Populations with at least 40 participants.
6. Follow-up of at least 2 years.
7. Publications reporting a quantitative summary of effect 
as a change from baseline, or an endpoint measure of 
at least one of seven prespecified outcomes.
i. Renal function, which could be measured by GFR, 
eGFR, creatinine clearance (CrCl) or estimated 
CrCl. This was our primary outcome of interest.
ii. Proteinuria, which could be measured by protein 
excretion rate (PER), protein creatinine ratio 
(PCR), albumin excretion rate (AER) or albumin 
creatinine ratio (ACR).
iii. Adverse events.
iv. Commencement of maintenance dialysis or kid-
ney transplantation.
v. Cardiovascular events.
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vi. Cardiovascular mortality.
vii. All-cause mortality.
We excluded trials that reported only data about popu-
lations that included people with CKD stage 5 to avoid 
underestimating the treatment effect, as we would expect 
stage 5 patients to have more comorbidities, which might 
lead to worse outcomes.
Data extraction and quality assessment
Data were extracted independently by two reviewers 
(KST, JM, NP and JYV; in pairs) using a data extraction 
form, which was piloted on a sample of five studies.
Extracted data included study details (setting, interven-
tion dose and frequency, follow-up period), information 
on study participants (age, gender, ethnicity, smoking 
status, blood pressure, CKD stage, existing comorbidi-
ties) and outcome data. For one study19 20 we extracted 
endpoint eGFR data from an earlier point than the 
longest follow-up as the patient numbers at the longest 
follow-up were so small (<7% of the population). We 
contacted study authors to seek clarification about data 
and to request data that could be included in our study.
The methodological quality of studies was assessed 
independently by two reviewers (KST, JM, NP and JYV; in 
pairs) using the Cochrane Risk of Bias Tool.21 This tool 
considers the method of random sequence generation 
and allocation concealment (selection bias), blinding 
of participants, personnel and outcomes (performance 
and detection biases), the levels and balance of missing 
outcome data (attrition bias), and completeness of 
reporting (selective reporting bias).
Disagreements about extracted data or methodological 
assessments were resolved by a third reviewer.
Data synthesis and analysis
We expected high statistical heterogeneity,22 but pooled 
data to give an indication of the average effect. We also 
pooled data when there were only two or three studies, 
although this could be potentially misleading, in order 
to give an indication of potential trends had there been 
more study data. We carried out random-effects analyses 
based on the DerSimonian and Laird method,23 assessed 
statistical heterogeneity using the I2 statistic and calcu-
lated approximate 95% prediction intervals to estimate 
the likely effects in a clinical setting24 using the methods 
of Higgins et al.25
For the continuous outcomes (renal function and 
proteinuria), we used a ratio of means (ROM)26 27 effect 
measure, which allowed us to combine data from trials 
that reported different measures of renal function or 
proteinuria in a single analysis. Using the ROM effect 
measure overcomes limitations of the well-established 
standardised mean difference (SMD),21 by providing units 
that are more easily interpreted than SDs, and avoiding 
the problems associated with presenting results with 
SDs, which can produce misleading results by deflating 
treatment effects for studies of heterogeneous popula-
tions and inflating treatment effects in homogeneous 
populations.28 We calculated the ROM as the ratio of the 
final eGFR in the intervention group to the final eGFR 
in the comparator group, so ROM >1 favoured the inter-
vention group for eGFR, where higher values are better 
than lower values. If a study of renal function reported 
reductions from baseline or rates of decline rather than 
endpoint data, we estimated the ROM of endpoints by the 
ratio of the reduction from baseline or rate of decline in 
the comparator group to that in the intervention group 
(the reciprocal) to ensure the direction of effect was 
consistent across all studies, as higher values of declining 
renal function are worse. ROM <1 favoured the inter-
vention group for the proteinuria outcomes (ACR, AER, 
PER, PCR), where higher values are worse.
For a few studies it was necessary to make further esti-
mates by approximating a mean using the median; esti-
mating SD from the IQR21; or estimating SE of ROM by 
imputation using the mean value of the known SEs of the 
other studies.
Meta-analysis was carried out on the log-transformed 
ROM and its SE. For the primary analysis, eGFR measured 
by the Modification of Diet in Renal Disease (MDRD) 
equation was selected over Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) data, as MDRD 
is the main equation advocated in clinical guidelines and 
CKD-EPI was not introduced until 20095 29; eGFR was also 
selected over CrCl. When analysing the effects of treat-
ments on proteinuria, we pooled data for PER, PCR, ACR 
and AER using a ROM effect measure. For the dichoto-
mous outcomes, we specified the relative risk (RR) as the 
effect measure.
We performed separate sensitivity analyses to ensure 
that our estimates of the effect of treatment in studies of 
patients with CKD stages 3 and 4 only (our main focus) 
were not sensitive to our choice of model, assumptions, 
quality of the studies, estimations made or our choices 
of data.
The following were the prespecified sensitivity analyses:
 ► Fixed-effect analyses based on the inverse-variance 
method were carried out for the continuous outcomes 
and based on the Mantel-Haenszel method for the 
dichotomous outcomes.30 31
 ► Excluding studies rated as low quality, which we 
defined as having a high risk of attrition bias or alloca-
tion concealment bias; studies rated as ‘unclear’ were 
not excluded.
 ► Excluding studies without intention-to-treat analysis. 
This was prespecified on the assumption that we would 
be dealing with primary studies of the progression of 
CKD, but as the studies were secondary or post-hoc 
this analysis was no longer relevant.
The following were further, standard set of sensitivity 
analyses:
 ► Excluding studies with estimates.
 ► Using more conservative estimates, considering those 
of the SE of ROM by imputing with the 75% percen-
tile value of the known SEs rather than the mean 
value, reflecting greater uncertainty.
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Figure 1 PRISMA diagram. PRISMA, Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses. CKD, 
chronic kidney disease; MDRD, Modification of Diet in Renal 
Disease.
 ► Using alternative data, considering CKD-EPI data 
instead of MDRD data, for studies that measured 
eGFR using both equations.
 ► Excluding studies that measured PCR and PER in the 
analysis of proteinuria, as urine albumin is a more 
accurate measure of glomerular damage.
 ► Excluding each individual study, one by one, to see if 
the level of heterogeneity depended on a particular 
study.
The following were post-hoc sensitivity analyses:
 ► Using the Hartung-Knapp-Sidik-Jonkman variance 
correction to calculate 95% CIs reflecting the uncer-
tainty in heterogeneity estimates.32–34
 ► Excluding studies with non-placebo controls.
Our prespecified subgroup analyses were by age (<65 or 
≥65 years), ethnicity, smoking status, intensity of interven-
tion, high blood pressure (≥140/90 mm Hg), low blood 
pressure (≤90/60 mm Hg), method of eGFR measure-
ment, degree of proteinuria in the renal function anal-
ysis, drug type within each drug class and by CKD stages 3 
and 4 separately. Heterogeneity was assessed using the I2 
statistic. Publication bias was explored using funnel plot 
analysis with contour plots.21 35
We used the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) framework21 to 
report the overall quality of evidence for the primary 
outcome (final eGFR). The certainty in the evidence for 
each outcome was graded as high, moderate, low or very 
low.
When describing the included trials, we refer to 
‘studies’ to encompass single trials and publications that 
report more than one trial. When reporting analyses of 
the effects of the drugs, we refer to populations as some 
studies reported data for CKD subgroups or dose-depen-
dent subgroups. All results of meta-analysis are displayed 
in forest plots and/or tabulated. Results are divided into 
those for studies of patients with CKD stages 3 and 4 only 
and studies of patients with CKD stages 3 and 4 mixed 
with patients with stages 1 and 2.
All analyses were carried out using STATA v.14.2,36 
except the risk of bias figures which were created in 
RevMan v.5.3.37
Patient involvement
Members of a patient and public involvement group were 
part of the Stakeholder Group and Steering Committee 
of the National Institute for Health Research (NIHR) 
Programme Grant that inspired this study. No patients 
or patient representatives were involved in setting the 
outcome measures, nor were they directly involved in 
developing plans for the design or implementation of 
the study. Three members of this group commented on 
our manuscript and we thank them for their help in the 
Acknowledgement section. A 1-day dissemination event 
is planned to report the results of all the studies funded 
by the NIHR Programme Grant, including this study. 
Members of the patient and public involvement group 
will be invited to this event.
RESulTS
Search results
Through database registry and hand searches, we identi-
fied 13 133 records (figure 1), of which 35 studies (51 155 
patients) satisfied our eligibility criteria.
Study characteristics
Most of the 35 studies reported data about a single trial, 
while 3 studies reported data about a pooled analysis of 
more than one trial.19 20 38–43 Of the 35 studies, 1 was from 
China,44 1 from Tasmania,45 3 from Japan,46–51 6 from 
USA/Canada,52–65 9 from Europe,13 66–78 either in single 
or multiple countries, and the other 15 studies were 
multinational (online supplementary material). Nine-
teen studies13 19 20 38–40 44 48–57 61–65 68–70 74 75 78–90 provided 
data for populations with CKD stages 3 and/or 4 only. 
These studies had between 108 and 3094 patients, and 
the mean or median follow-up was between 24 and 66 
months.
One study67 had a 2×2 factorial design involving an antihy-
pertensive drug and a lipid-modifying drug, and this study 
is included in our analysis of both antihypertensive drugs 
and lipid-modifying drugs. Another study had a 2×271 72 
factorial design involving two antihypertensive drugs and 
a lipid-modifying drug, and this study is only included in 
our analysis of lipid-modifying drugs because all patients 
received antihypertensives. The other 33 studies were 12 
studies of antihypertensives,16 38–40 44 46 47 52–57 66 67 79–83 91–98 
13 of lipid-modifying drugs,45 48–51 58–63 68–70 73–78 84–86 99–104 
6 of glycaemic control agents19 20 41–43 87–90 105–107 and 2 of 
sodium bicarbonate13 64 65 (online supplementary mate-
rial). Four studies45 58–60 73 102–104 had populations with 
CKD and no comorbidities highlighted, 27 studies had 
a single comorbidity, and 4 studies had more than one 
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Figure 2 ROM of estimated glomerular filtration rate at the 
end of the trials for antihypertensives versus comparator 
(boxes) and pooled estimates across studies (diamonds) 
calculated by the random-effects DerSimonian and Laird 
method, split by CKD stage. CHARMa and CHARMb, CKD 
stages 3 and 4, respectively, with estimated glomerular 
filtration rate measured by the MDRD equation. IDNTa, 
intervention is irbesartan; IDNTb, intervention is amlodipine. 
CKD, chronic kidney disease; MDRD, Modification of Diet in 
Renal Disease; ROM, ratio of means.
comorbidity. Comorbidities were cardiovascular in 19 
studies19 20 38–43 46–51 53 54 57 61–63 68–72 74–78 81–83 89–92 98–101; type 
II diabetes in 9 studies19 20 41–43 53–56 79 80 87–90 93–97 105–107 
(including all 6 studies of glycaemic control drugs); and 
a renal disorder or damage (idiopathic chronic glomeru-
lonephritis, advanced chronic renal insufficiency without 
diabetes, advanced autosomal dominant polycystic kidney 
disease, renal impairment and metabolic acidosis) in 7 
studies13 44 52 64–67 84–86 (online supplementary material). 
In 15 studies,13 45–47 61–67 71–73 76 77 91–99 107 the population 
analysed for our primary outcome was the whole trial 
population, and in the other 20 the population analysed 
was a subgroup of the trial population, reported as either 
a subgroup or post-hoc analysis (online supplementary 
material).
Baseline data were provided for the same popula-
tion as that included in our analyses for 19 of the 35 
studies13 45 49–51 58–70 73 76–80 84–88 91–98 107; for the other 16 
studies, baseline data were only provided for either a 
different subset of the trial population or the whole trial 
population (online supplementary material).
Risk of bias
We considered the methodological quality of all 35 
eligible studies (online supplementary material), based 
on the design of the trial(s) from which data were 
obtained. Eight studies19 20 44 71–73 84–88 98 105 106 were ranked 
with high quality as they had ‘Low’ risk of bias across all 
domains, and we rated one study76 77 as ‘High’ risk of bias 
for three domains and ‘Unclear’ across two domains. 
Most studies described their method of randomisation, 
but fewer studies were clear about how they concealed 
the group allocation and whether participants, personnel 
and outcome assessors were blinded. The risk of attrition 
bias was high in nearly a quarter of the studies.
We had sufficient data to consider the possibility of 
publication bias based on the primary outcome of renal 
function in those taking antihypertensive and lipid-modi-
fying drugs. The contour-enhanced funnel plots suggested 
possible publication bias, as few studies were in the area 
of non-significance (online supplementary material).
Renal function
Most of the available data were on eGFR.
The pooled ROM of eGFR for antihypertensive drugs 
versus comparators at the end of the studies is shown 
in figure 2. There was no significant effect in studies of 
populations with CKD stages 3 and 4, and heterogeneity 
between studies was substantial at 94% (yielding a predic-
tion interval of 0.79–1.34), and this was not attributable 
to a single study. Adding data from the studies of patients 
that included those with CKD stages 1 and/or 2 increased 
the benefit to the intervention group but not significantly. 
All except one study (Bianchi et al66) had placebo controls. 
All the sensitivity analyses produced similar results of no 
significant treatment effect and heterogeneity remained 
substantial (online supplementary material).
The only subgroup analysis that was possible, of those 
prespecified, was by drug type within the antihypertensive 
drug class. Among studies of CKD stages 3 and 4 only, 
there were no significant treatment effects within the 
different drug types (online supplementary material), 
except in the case of calcium channel blockers, where the 
endpoint eGFR was 14% higher in the intervention group 
(ROM 1.14, 95% CI 1.01 to 1.27), but this was based on a 
single study.53 54
In studies of patients with CKD stages 3 and 4, there was 
a marginally higher benefit to those taking the lipid-mod-
ifying drugs (figure 3), as the endpoint eGFR was 4% 
higher (ROM 1.04, 1.00 to 1.08, statistically significant, 
I2=88; STATA’s metaninf command produced output that 
indicated that the lower confidence bound was 1.0001 to 
4 decimal places) with a prediction interval of 0.91–1.18. 
This result was not robust as the results of sensitivity anal-
ysis were variable (online supplementary material). The 
high degree of heterogeneity was attributed to the Study 
of Heart and Renal Protection102–104 of the CKD stage 4 
subgroup, as removing this study reduced I2 from 88.3% 
to 45.3%. The intervention for this study was a higher dose 
of statin than in the other studies, and another lipid-mod-
ifying drug, ezetimibe, was also used. Adding data from 
the studies of patients including those with CKD stages 1 
and/or 2 increased the benefit to the intervention group 
but not significantly, and there was substantial heteroge-
neity between studies (I2=98%). Three trials had non-pla-
cebo controls (ASUCA,48 MEGA49–51 and GREACE76 77).
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Figure 3 ROM of estimated glomerular filtration rate at the 
end of the trials for lipid-modifying drugs versus comparator 
(boxes) and pooled estimates across studies (diamonds) 
calculated by the random-effects DerSimonian and Laird 
method, split by CKD stage. ASCOT-LLAa, atorvastatin and 
amlodipine versus placebo and amlodipine; ASCOT-LLAb, 
atorvastatin and atenolol versus placebo and atenolol; GISSI-
HFa, CKD stage 3; GISSI-HFb, CKD stage 4; GREACEa, 
atorvastatin versus usual care for the group with metabolic 
syndrome; GREACEb, atorvastatin versus usual care for the 
group without metabolic syndrome; SHARPa, CKD stages 
1–3; SHARPb, CKD stage 4. CKD, chronic kidney disease; 
ROM, ratio of means; SHARP, Study of Heart and Renal 
Protection.
Figure 4 ROM of estimated glomerular filtration rate at 
the end of the trials for glycaemic control drugs versus 
comparator (boxes) and pooled estimates across studies 
(diamonds) calculated by the random-effects DerSimonian 
and Laird method, split by CKD stage. Bode 2015L, 
intervention is low-dose canagliflozin (100 mg per day); Bode 
2015H,intervention is high-dose canagliflozin (300 mg per 
day); EMPA-REG H, intervention is high-dose empagliflozin 
(25 mg daily); EMPA-REG L, intervention is low-dose 
empagliflozin (10 mg daily); Kohan 2014L, intervention is low-
dose dapagliflozin (5 mg per day); Kohan 2014H, intervention 
is high-dose dapagliflozin (10 mg per day); CANVASa, CKD 
stage 3a; CANVASb, CKD stage 3b; TECOSa, CKD stage 3a; 
TECOSb, CKD stage 3b. CKD, chronic kidney disease; ROM, 
ratio of means.
There was a significant benefit to those taking 
glycaemic controlling drugs (figure 4) as the mean eGFR 
at the end of the study was 6% higher in the intervention 
group (ROM 1.06, 1.02 to 1.10). Heterogeneity between 
studies was low (I2=0%), yielding a prediction interval 
of 1.01–1.11. Sensitivity analyses showed that this result 
was robust (online supplementary material). Adding the 
CKD stage 1–4 studies, there was no significant difference 
between the intervention and comparator groups, and 
the heterogeneity between studies was high (I2=85%). In 
all studies the comparator groups received placebo drugs. 
We assessed the outlier41–43 as having high attrition bias, 
as of the 1887 who were randomised only 487 completed 
the 104-day study period. After excluding this study, there 
was a significant benefit to the intervention group, which 
was similar to that for the studies of patients with CKD 
stages 3 and 4.
A study64 65 of patients with CKD stage 3 reported a 22% 
higher endpoint eGFR from taking sodium bicarbonate 
(ROM 1.22, 1.10 to 1.36). Another study13 of patients 
with CKD stage 4 reported that taking sodium bicar-
bonate produced no significant effect on renal function 
in terms of CrCl (ROM 0.94, 0.85 to 1.05). Pooling these 
data, there was no significant treatment effect based on 
renal function (online supplementary material). In both 
studies the comparator groups received routine care.
Figure 5 summarises the effects of treatment on renal 
function by drug class for the four drug classes.
The GRADE confidence in these estimates was very low 
for our analysis of antihypertensive drugs, lipid-regulating 
drugs and sodium bicarbonate, and low for our analysis of 
glycaemic control drugs.
Proteinuria
Data pooling for proteinuria was possible only for antihy-
pertensive drugs in five studies. For studies of CKD stages 
3 and 4 and overall, there was no significant treatment 
effect (online supplementary material), with ROM of 
0.91 (0.78 to 1.05) and low heterogeneity at 41.3%. All 
sensitivity analyses produced the same result of no treat-
ment effect with low heterogeneity (online supplemen-
tary material).
Two studies of lipid-modifying drugs presented protein-
uria. The ATIC study73 of patients with CKD stages 2–4 
reported that treatment reduced urinary albumin excre-
tion and provided medians and ranges of the AER (77, 
3–2509 mg/24 hours for the intervention group, and 107, 
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Figure 6 Relative risk (RR) of cardiovascular disease during 
trials of lipid-modifying drugs versus comparator (boxes) and 
pooled estimates across trials (diamonds) calculated by the 
random-effects DerSimonian and Laird method, split by CKD 
stage. GREACEa, atorvastatin versus usual care for the group 
with metabolic syndrome; GREACEb, atorvastatin versus 
usual care for the group without metabolic syndrome. CKD, 
chronic kidney disease.
Figure 5 Effect of treatment on estimated glomerular 
filtration rate by drug class: CKD stages 3 and 4 only. ROM 
>1 favoured the intervention group (higher values are better). 
‘Studies’ refers to the study of different populations. Of the 
35 included studies, 15 reported renal function of patients 
with CKD stage 3 and/or stage 4. Of these, 9 reported renal 
function of a single population and 6 reported results for two 
CKD subgroups or dose-dependent subgroups. CKD, chronic 
kidney disease; ROM, ratio of means.
5–3545 mg/24 hours for the comparator group). The 
PREVEND IT lipid study67 of patients with CKD stages 
1–3 reported that treatment slightly increased urinary 
albumin excretion by quoting medians and IQRs (21.8 
and 11.6–41.9 mg/24 hours for the intervention group, 
and 20.3 and 12.5–40.5 mg/24 hours for the control 
group).
One glycaemic control study presented proteinuria as 
an outcome. The CANVAS programme19 20 reported that 
treatment significantly reduced albuminuria compared 
with the placebo group. ACR was expressed on the 
geometric mean scale, as 13% lower in the intervention 
group compared with the controls (95% CI 1% to 24%) 
in patients with CKD stage 3a, and 26% lower (95% CI 
20% to 31%) in patients with CKD stages 3b and 4.
One sodium bicarbonate study64 65 reported that treat-
ment lowered the ACR by quoting a median (IQR) of 
257.1 (205.5–305.0 mg/g creatinine) for the intervention 
group and 300.3 (241.8–347.5 mg/g creatinine) for the 
control group.
Adverse events
There were no significant differences in the risk of adverse 
events in the studies of antihypertensives, lipid-modi-
fying drugs and glycaemic control agents (online supple-
mentary material). Neither of the bicarbonate studies 
reported adverse events.
Maintenance dialysis and kidney transplantation
Two studies of antihypertensive drugs reported the 
number of patients who deteriorated and required 
maintenance dialysis or kidney transplantation. The risk 
in the intervention group was 31% lower than in the 
control group in the HALT PKD study52 of patients with 
stages 3 and 4 CKD (RR 0.69, 95% CI 0.50 to 0.96). In 
the RENAAL study,93–97 which was based on patients with 
CKD stages 2–4, treatment with antihypertensives led to 
a 23% reduction in risk of deterioration to kidney failure 
(RR 0.77, 95% CI 0.64 to 0.93). There were no significant 
differences in this outcome in the studies of lipid-mod-
ifying drugs or glycaemic control drugs (online supple-
mentary material).
Cardiovascular events
There were no significant differences between the inter-
vention and control groups in the risk of cardiovascular 
events in the studies of antihypertensives, whereas treat-
ment with lipid-modifying drugs led to a reduction in risk 
of 36% (RR 0.64, 95% CI 0.52 to 0.80, I2=30%) (figure 6). 
All the sensitivity analyses yielded similar results and 
heterogeneity generally remained low (online supple-
mentary material). The reduction in risk was slightly 
higher when data were added from the studies of patients 
that included those with CKD stages 1 and/or 2, but this 
reduction in risk was not significant (online supplemen-
tary material).
The TECOS glycaemic control study89 90 reported the 
number of patients who experienced cardiovascular 
events in patients with CKD stage 3. They reported no 
significant differences between the intervention and 
control groups (online supplementary material).
Mortality
In both our analyses of the studies of antihypertensive 
drugs and glycaemic control drugs, we found no signif-
icant differences, between the intervention and compar-
ator groups, in the risk of cardiovascular mortality and 
all-cause mortality (online supplementary material).
Two studies reported the effect of lipid-modifying drugs 
on the risk of cardiovascular mortality in patients with 
CKD stages 3 and 4. In the FIELD study,84–86 the risk was 
47% lower in the intervention group (RR 0.53, 95% CI 
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Figure 7 Relative risk (RR) of all-cause mortality during 
trials of lipid-modifying drugs versus comparator (boxes) and 
pooled estimates across trials (diamonds) calculated by the 
random-effects DerSimonian and Laird method, split by CKD 
stage. GREACEa, atorvastatin versus usual care for the group 
with metabolic syndrome; GREACEb, atorvastatin versus 
usual care for the group without metabolic syndrome. CKD, 
chronic kidney disease.
0.30 to 0.92), and in the AFCAPS/TEXCAPS study58–60 
there was no significant difference.
In the studies of patients with CKD stages 3 and 4 only, 
treatment with lipid-modifying drugs reduced the risk of 
all-cause mortality by 26% (RR 0.74, 95% CI 0.56 to 0.98) 
(figure 7 and online supplementary material).
DISCuSSIOn
Main findings
We found limited data on the effects of antihypertensive, 
lipid-modifying and glycaemic control drugs and sodium 
bicarbonate on the progression of renal function in 
patients with CKD stages 3 and 4. There was heterogeneity 
of patient populations in the included studies. Pooling 
data provided no pooled evidence of benefit or impair-
ment of renal function in these patients attributable to 
antihypertensive drugs. There was some suggestion of 
benefit to renal function from taking glycaemic control 
drugs and lipid-modifying drugs, and a clear reduction 
in cardiovascular disease and all-cause mortality by taking 
lipid-modifying drugs. There was insufficient evidence to 
draw any conclusions about sodium bicarbonate. There 
were only sufficient data to study the effects of antihyper-
tensive drugs on proteinuria and we found no significant 
treatment effect.
Comparison with other reviews
Our review is comparable with two reviews of drug inter-
ventions in patients with CKD, as they report changes in 
eGFR as outcome measures. Our findings on the protec-
tive effect of lipid-modifying drugs are consistent with 
the findings of Sandhu et al,9 who concluded that statins 
produce a small reduction in the progression of CKD 
in patients with cardiovascular disease. Our results are 
also consistent with those of Lewis et al,16 who reported 
the preliminary results of a review that considered the 
effect on kidney function of lowering low-density lipo-
protein cholesterol with statins. Their preliminary find-
ings suggested that for patients taking statins there was 
a highly significant reduction in the annual rate of CKD 
progression compared with control groups (based on the 
annual rate of change in eGFR). Both of these studies 
considered general populations with CKD. Our finding 
that lipid-modifying drugs reduce the risk of cardiovas-
cular events and all-cause mortality also concurs with 
other reviews of patients with CKD.108–110
Strengths and limitations
Our study is a first attempt to summarise the literature 
on drug treatment for patients with CKD types 3 and 4. 
We have identified, evaluated and compared the effects 
of different drug interventions on reducing the rate of 
CKD progression in patients with CKD stages 3 and 4. By 
focusing on this patient group, we took a primary care 
perspective on the management of CKD. Our search was 
extensive and comprehensive, with no restrictions on 
language or publication type. By using the ROM as the 
effect measure for continuous outcomes, we were able to 
pool data on different measures in a single analysis and 
overcome the limitations of the more established SMD. 
This provided an overall indication of the treatment 
effect, as did pooling data in cases where there were few 
studies or a high degree of heterogeneity. The generalis-
ability of our findings is limited by the paucity of studies, 
the high degree of statistical heterogeneity, and clinical 
heterogeneity in terms of comorbidities and treatment 
interventions. We concluded that clinical heterogeneity 
was inevitable in studies in these patients, as most were 
undergoing treatment with background medications. 
Paucity of data restricted our ability to explore the base-
line characteristics of studies and the effects of lipid-mod-
ifying drugs, glycaemic control drugs and bicarbonates, 
particularly on proteinuria and our other secondary 
outcomes. We were also restricted in our ability to investi-
gate the link between treatment effect and drug dose and 
assess publication bias fully. There was a wide variation 
of study characteristics (in terms of population size and 
follow-up period) and baseline characteristics (in terms 
of male/female split, smoking status, ethnicity and hyper-
tensive status). The generalisability of the findings is also 
limited by the effect of drugs on CKD being secondary 
in all the studies. For example, antihypertensives target 
hypertension and glycaemic control drugs target diabetes. 
Our ability to assess the quality of the included studies was 
restricted, because for nearly half the studies we could 
not assess allocation concealment bias, and for around a 
quarter of the studies we could not ascertain the risk of 
attrition bias or whether the participants, personnel and 
outcomes assessors had been blinded. Further bias may 
have arisen as most of the reports in our included studies 
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were subgroup or post-hoc analyses of trials. The balance 
achieved by randomising the whole trial population may 
not apply to subgroups of patients. However, we were 
unable to check this as few of these studies reported the 
necessary baseline characteristics, split by intervention 
group. Few studies reported the use of maintenance dial-
ysis and kidney transplantation, which may be considered 
to be more appropriate survival outcomes for patients 
with CKD stages 3 and 4, compared with mortality. Limita-
tions may also arise from the possible impact on patient 
management decisions following the introduction of CKD 
staging in 2002. Before that, patients were treated on the 
basis of the perceived cause of CKD rather than the CKD 
itself. A number of the included studies had recruitment 
periods that began before 2002, so their populations 
would be a mixture of patients managed under the old 
and new guidance. However, in spite of all these limita-
tions, the results of our analyses are consistent with those 
of other studies.
Implications for clinical practice and future research
In populations with CKD stages 3 and 4, lipid-modifying 
drugs and glycaemic control drugs may improve renal 
function, and lipid-modifying drugs are associated with a 
reduction in cardiovascular events. Although antihyper-
tensive drugs and sodium bicarbonate are presumed to 
reduce CKD progression,8 11–13 we did not find a signifi-
cant treatment effect. However, the paucity of data and 
high heterogeneity do not allow strong recommendations 
for clinical practice. Therefore, future research is needed 
into the effects of drugs on the progression in CKD, in 
particular in studies that focus on CKD progression as a 
primary outcome.
Our finding of limited data is important given that CKD 
is a common progressive disease. The drugs we consid-
ered are commonly used, but studies have concentrated 
on cardiovascular outcomes and not CKD outcomes.
COnCluSIOnS
This review suggests that glycaemic control and lipid 
regulation may improve renal function in patients with 
moderate CKD. There was no pooled evidence of either 
benefit or harm from antihypertensive drugs. However, 
the data were limited and heterogeneity was high for many 
of the analyses. Therefore, our findings are tentative.
Author affiliations
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, 
UK
2Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium
3Institute of Applied Health Research, University of Birmingham, Birmingham, UK
4Bodleian Health Care Libraries, University of Oxford, Oxford, UK
5John Radcliffe Hospital, Oxford Radcliffe Hospitals Trust, Oxford, UK
6Farr Institute of Health Informatics Research, University College London, London, 
UK
Acknowledgements We would like to thank all those who clarified our queries 
about their trials and/or provided additional data, including Professor Nathaniel 
Hawkins, Professor Fan Fan Hou, Ms Jennifer Meessen, Professor Bruce Neal, 
Professor Valdo Perkovic, Dr Ruth Peters, Professor Scott D Solomon, Dr Di Xie and 
a number of anonymous others. We would also like to acknowledge all those who 
provided data and/or clarification about their trials which, unfortunately, we were 
unable to include in our study, including Professor Fan Fan Hou and Dr Di Xie, Mr 
Colin Bicknell, Professor Bob Byington, Dr Enayet Karim Chowdhury, Professor Fan 
Fan Hou, Dr Dipak Kotecha, Dr Javier Martinez-Martin, Professor John McMurray, 
Dr Robert G Nelson, Nove Nordisk, Hiromi Rakugi MD, Dr Marcello Tonelli, 
Professor William White, Dr Di Xie and Professor Keng Thye Woo. Thanks also to 
Dr Boby Mihaylova, who helped produce the protocol for this review; Dr Richard 
Stevens, who provided some statistical advice; Dr Brian Shine, who provided 
advice on pooling different measures of CKD and proteinuria; Professor Paul 
Glasziou, Dr Boby Mihaylova, and from the Patient and Public Involvement Group, 
Dr Elizabeth Holloway, Dr Peter Kirby and Mrs Rachael Patel, for their comments 
about the manuscript and helpful suggestions that have improved the text; and 
the Stakeholder Group and Steering Committee of our NIHR Programme Grant, for 
discussions that inspired this paper.
Contributors JM, RP, CRB, JYV, JKA, DSL, CAOC, KT, FDRH and AB were involved 
in the conception and design of the study. NR, assisted by JM and JKA, devised 
the search strategy. NR completed the search. JM, NP, KST, JYV and SF selected 
studies for inclusion, and KST, JM, JYV and NP extracted data. KST carried out the 
data analysis with advice from RP. KST and JM together wrote the first draft of 
the manuscript, and all authors contributed critically to subsequent revisions and 
approved the final manuscript. KST and JM had full access to all data in the study 
and take responsibility for the integrity and accuracy of the data analysis. KST and 
JM are guarantors.
Funding This article presents independent research funded by the NIHR under 
the Programme Grants for Applied Research (RP-PG-1210-12003). The views 
expressed are those of the authors and not necessarily those of the NHS, the NIHR 
or the Department of Health.
Competing interests KST, JM, JKA and SF receive funding from the NIHR 
Programme for Applied Research. JYV receives funding from the NIHR Community 
Healthcare MIC, Nuffield Department of Primary Care Health Sciences and 
University of Oxford NIHR Diagnostic Evidence Co-operative (DEC). DSL receives 
funding from the NIHR Community Healthcare MIC. FDRH acknowledges his part-
funding from the National Institute for Health Research (NIHR) School for Primary 
Care Research, the NIHR Collaboration for Leadership in Health Research and Care 
(CLAHRC) Oxford, the NIHR Oxford Biomedical Research Centre (BRC) (UHT), and 
the NIHR Oxford Medtech and In Vitro Diagnostics Co-operative (MIC). RP receives 
funding from the NIHR Oxford Biomedical Research Centre Programme, the NIHR 
Programme for Applied Research, the NIHR HPRU Gastrointestinal Infections Group, 
and the NIHR Diagnostic Evidence Co-operative (DEC). 
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
REFEREnCES
 1. Hill NR, Fatoba ST, Oke JL, et al. Global Prevalence of Chronic 
Kidney Disease - A Systematic Review and Meta-Analysis. PLoS 
One 2016;11:e0158765.
 2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the 
risks of death, cardiovascular events, and hospitalization. N Engl J 
Med 2004;351:1296–305.
 3. National Institute for Health and Care Excellence. Chronic kidney 
disease: early identification and management of chronic kidney 
disease in adults in primary and secondary care (CG182. London: 
National Clinical Guideline Centre, 2014.
 4. Levey AS, Eckardt K-U, Tsukamoto Y, et al. Definition and 
classification of chronic kidney disease: a position statement from 
kidney disease: improving global outcomes (KDIGO). Kidney Int 
2005;67:2089–100.
 5. Levin A, Stevens PE. Summary of KDIGO 2012 CKD guideline: 
behind the scenes, need for guidance, and a framework for moving 
forward. Kidney Int 2014;85:49–61.
Protected by copyright.
 o
n
 O
ctober 21, 2019 at Barnes Library M
edical School.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030596 on 20 September 2019. Downloaded from 
10 Taylor KS, et al. BMJ Open 2019;9:e030596. doi:10.1136/bmjopen-2019-030596
Open access 
 6. de Lusignan S, Tomson C, Harris K, et al. UK Prevalence of Chronic 
Kidney Disease for the Adult Population Is 6.76% Based on Two 
Creatinine Readings. Nephron Clin Pract 2012;120:107–c07.
 7. Oke J, Shine B, McFadden E, et al. Trends in serum creatinine 
testing in Oxfordshire, UK, 1993-2013: a population-based cohort 
study. BMJ Open 2015;5:e009459.
 8. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, 
proteinuria, and the progression of renal disease. the modification 
of diet in renal disease study. Ann Intern Med 1995;123:754–62.
 9. Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal 
outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006–16.
 10. Wang PH, Lau J, Chalmers TC. Meta-Analysis of effects of intensive 
blood-glucose control on late complications of type I diabetes. 
Lancet 1993;341:1306–9.
 11. Phisitkul S, Khanna A, Simoni J, et al. Amelioration of metabolic 
acidosis in patients with low GFR reduced kidney endothelin 
production and kidney injury, and better preserved GFR. Kidney Int 
2010;77:617–23.
 12. Mahajan A, Simoni J, Sheather SJ, et al. Daily oral sodium 
bicarbonate preserves glomerular filtration rate by slowing 
its decline in early hypertensive nephropathy. Kidney Int 
2010;78:303–9.
 13. de Brito-Ashurst I, Varagunam M, Raftery MJ, et al. Bicarbonate 
supplementation slows progression of CKD and improves nutritional 
status. J Am Soc Nephrol 2009;20:2075–84.
 14. Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood 
pressure lowering on the progression of chronic kidney disease: a 
systematic review and meta-analysis. CMAJ 2013;185:949–57.
 15. Bakris GL. Slowing nephropathy progression: focus on proteinuria 
reduction. Clin J Am Soc Nephrol 2008;3(Suppl 1):S3–S10.
 16. Lewis A, Emberson JR, Blackwell LJ, et al. Effect of lowering LDL-
cholesterol on kidney function: meta-analysis of data from 120,000 
participants in 21 randomized trials. Abstract supplement. J Am 
Soc Nephrol 2012;23:685A.
 17. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that 
evaluate healthcare interventions: explanation and elaboration. BMJ 
2009;339:b2700.
 18. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to 
estimate glomerular filtration rate from serum creatinine: a new 
prediction equation. Modification of diet in renal disease study 
group. Ann Intern Med 1999;130:461–70.
 19. Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal 
outcomes with canagliflozin according to baseline kidney function. 
Circulation 2018;138:1537–50.
 20. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and 
cardiovascular and renal events in type 2 diabetes. N Engl J Med 
2017;377:644–57.
 21. Higgins JPT, Green S. Cochrane Handbook for systematic reviews 
of interventions. New Jersey, United States: Wiley-Blackwell, 2011.
 22. Higgins JPT. Commentary: heterogeneity in meta-analysis 
should be expected and appropriately quantified. Int J Epidemiol 
2008;37:1158–60.
 23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin 
Trials 1986;7:177–88.
 24. Riley RD, Higgins JPT, Deeks JJ. Interpretation of random effects 
meta-analyses. BMJ 2011;342:d549.
 25. Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation 
of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc 
2009;172:137–59.
 26. Friedrich JO, Adhikari NKJ, Beyene J. The ratio of means method 
as an alternative to mean differences for analyzing continuous 
outcome variables in meta-analysis: a simulation study. BMC Med 
Res Methodol 2008;8:32.
 27. Friedrich JO, Adhikari NKJ, Beyene J. Ratio of means for analyzing 
continuous outcomes in meta-analysis performed as well as mean 
difference methods. J Clin Epidemiol 2011;64:556–64.
 28. Guyatt GH, Thorlund K, Oxman AD, et al. Grade guidelines: 13. 
preparing summary of findings tables and evidence profiles-
continuous outcomes. J Clin Epidemiol 2013;66:173–83.
 29. Levey AS, Stevens LA, Schmid CH, et al. A new equation 
to estimate glomerular filtration rate. Ann Intern Med 
2009;150:604–12.
 30. Mantel N, Haenszel W. Statistical aspects of the analysis of 
data from retrospective studies of disease. J Natl Cancer Inst 
1959;22:719–48.
 31. Greenland S, Robins JM. Estimation of a common effect parameter 
from sparse follow-up data. Biometrics 1985;41:55–68.
 32. Cornell JE, Mulrow CD, Localio R, et al. Random-effects meta-
analysis of inconsistent effects: a time for change. Ann Intern Med 
2014;160:267–70.
 33. Röver C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman 
approach and its modification for random-effects meta-analysis 
with few studies. BMC Med Res Methodol 2015;15:99.
 34. Hartung J, Knapp G. A refined method for the meta-analysis 
of controlled clinical trials with binary outcome. Stat Med 
2001;20:3875–89.
 35. Peters JL, Sutton AJ, Jones DR, et al. Contour-enhanced meta-
analysis funnel plots help distinguish publication bias from other 
causes of asymmetry. J Clin Epidemiol 2008;61:991–6.
 36. StataCorp. Stata statistical software: release 14 [program. College 
Station, TX: StataCorp LP, 2015.
 37. Cochrane Community. Review Manager (RevMan) [Computer 
program. Version 5.3. Copenhagen: The Nordic Cochrane Centre, 
The Cochrane Collaboration, 2014.
 38. Hawkins NM, Jhund PS, Pozzi A, et al. Severity of renal impairment 
in patients with heart failure and atrial fibrillation: implications for 
non-vitamin K antagonist oral anticoagulant dose adjustment. Eur J 
Heart Fail 2016;18:1162–71.
 39. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor 
of outcome in a broad spectrum of patients with heart failure. 
Circulation 2006;113:671–8.
 40. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan 
on mortality and morbidity in patients with chronic heart failure: the 
CHARM-Overall programme. Lancet 2003;362:759–66.
 41. Leiter LA, Cefalu WT, de Bruin TWA, et al. Long-term maintenance 
of efficacy of dapagliflozin in patients with type 2 diabetes mellitus 
and cardiovascular disease. Diabetes Obes Metab 2016;18:766–74.
 42. Cefalu WT, Leiter LA, de Bruin TWA, et al. Dapagliflozin's effects on 
glycemia and cardiovascular risk factors in high-risk patients with 
type 2 diabetes: a 24-week, multicenter, randomized, double-blind, 
placebo-controlled study with a 28-Week extension. Diabetes Care 
2015;38:1218–27.
 43. Leiter LA, Cefalu WT, de Bruin TWA, et al. Dapagliflozin added 
to usual care in individuals with type 2 diabetes mellitus with 
preexisting cardiovascular disease: a 24-week, multicenter, 
randomized, double-blind, placebo-controlled study with a 28-week 
extension. J Am Geriatr Soc 2014;62:1252–62.
 44. Hou FF, Zhang X, Zhang GH, et al. Efficacy and safety of 
benazepril for advanced chronic renal insufficiency. N Engl J Med 
2006;354:131–40.
 45. Fassett RG, Robertson IK, Ball MJ, et al. Effect of atorvastatin on 
kidney function in chronic kidney disease: a randomised double-
blind placebo-controlled trial. Atherosclerosis 2010;213:218–24.
 46. Sakata Y, Shiba N, Takahashi J, et al. Clinical impacts of additive 
use of olmesartan in hypertensive patients with chronic heart 
failure: the supplemental benefit of an angiotensin receptor blocker 
in hypertensive patients with stable heart failure using olmesartan 
(support) trial. Eur Heart J 2015;36:915–23.
 47. Sakata Y, Nochioka K, Miura M, et al. Supplemental benefit of an 
angiotensin receptor blocker in hypertensive patients with stable 
heart failure using olmesartan (SUPPORT) trial--rationale and 
design. J Cardiol 2013;62:31–6.
 48. Kimura G, Kasahara M, Ueshima K, et al. Effects of atorvastatin 
on renal function in patients with dyslipidemia and chronic kidney 
disease: assessment of clinical usefulness in CKD patients with 
atorvastatin (ASUCA) trial. Clin Exp Nephrol 2017;21:417–24.
 49. Management of Elevated Cholesterol in the Primary Prevention 
Group of Adult Japanese (MEGA) Study Group. Design and baseline 
characteristics of a study of primary prevention of coronary events 
with pravastatin among Japanese with mildly elevated cholesterol 
levels. Circ J 2004;68:860–7.
 50. Nakamura H, Mizuno K, Ohashi Y, et al. Pravastatin and 
cardiovascular risk in moderate chronic kidney disease. 
Atherosclerosis 2009;206:512–7.
 51. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of 
cardiovascular disease with pravastatin in Japan (MEGA study): a 
prospective randomised controlled trial. Lancet 2006;368:1155–63.
 52. Torres VE, Abebe KZ, Chapman AB, et al. Angiotensin blockade in 
late autosomal dominant polycystic kidney disease. N Engl J Med 
2014;371:2267–76.
 53. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective 
effect of the angiotensin-receptor antagonist irbesartan in 
patients with nephropathy due to type 2 diabetes. N Engl J Med 
2001;345:851–60.
 54. Evans M, Bain SC, Hogan S, et al. Irbesartan delays progression 
of nephropathy as measured by estimated glomerular filtration 
rate: post hoc analysis of the irbesartan diabetic nephropathy trial. 
Nephrol Dial Transplant 2012;27:2255–63.
 55. Berl T, Hunsicker LG, Lewis JB, et al. Cardiovascular outcomes 
in the irbesartan diabetic nephropathy trial of patients with type 2 
diabetes and overt nephropathy. Ann Intern Med 2003;138:542–9.
Protected by copyright.
 o
n
 O
ctober 21, 2019 at Barnes Library M
edical School.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030596 on 20 September 2019. Downloaded from 
11Taylor KS, et al. BMJ Open 2019;9:e030596. doi:10.1136/bmjopen-2019-030596
Open access
 56. Lambers Heerspink HJ, Weldegiorgis M, Inker LA, et al. Estimated 
GFR decline as a surrogate end point for kidney failure: a post hoc 
analysis from the reduction of end points in non-insulin-dependent 
diabetes with the angiotensin II antagonist losartan (RENAAL) study 
and irbesartan diabetic nephropathy trial (IDNT). Am J Kidney Dis 
2014;63:244–50.
 57. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of captopril on 
mortality and morbidity in patients with left ventricular dysfunction 
after myocardial infarction. Results of the survival and ventricular 
enlargement trial. The SAVE Investigators. N Engl J Med 
1992;327:669–77.
 58. Downs JR, Clearfield M, Weis S, et al. Primary prevention of 
acute coronary events with lovastatin in men and women with 
average cholesterol levels: results of AFCAPS/TexCAPS. Air 
Force/Texas coronary atherosclerosis prevention study. JAMA 
1998;279:1615–22.
 59. Kendrick J, Shlipak MG, Targher G, et al. Effect of lovastatin on 
primary prevention of cardiovascular events in mild CKD and kidney 
function loss: a post hoc analysis of the air Force/Texas coronary 
atherosclerosis prevention study. Am J Kidney Dis 2010;55:42–9.
 60. Downs JR, Beere PA, Whitney E, et al. Design & rationale of the Air 
Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS). Am J Cardiol 1997;80:287–93.
 61. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil 
treatment and lipid levels with major coronary events: VA-HIT: a 
randomized controlled trial. JAMA 2001;285:1585–91.
 62. Tonelli M, Collins D, Robins S, et al. Effect of gemfibrozil on change 
in renal function in men with moderate chronic renal insufficiency 
and coronary disease. Am J Kidney Dis 2004;44:832–9.
 63. Rubins HB, Robins SJ, Iwane MK, et al. Rationale and design of the 
Department of Veterans Affairs high-density lipoprotein cholesterol 
intervention trial (HIT) for secondary prevention of coronary artery 
disease in men with low high-density lipoprotein cholesterol 
and desirable low-density lipoprotein cholesterol. Am J Cardiol 
1993;71:45–52.
 64. Goraya N, Munoz-Maldonado Y, Simoni J. Treatment of metabolic 
acidosis in chronic kidney disease with fruits and vegetables but 
not sodium bicarbonate yields fewer adverse cardiovascular events 
after five-years follow up. Circulation Conference: Resuscitation 
Science Symposium, ReSS, 2017.
 65. Goraya N, Simoni J, Jo C-H, et al. Treatment of metabolic acidosis 
in patients with stage 3 chronic kidney disease with fruits and 
vegetables or oral bicarbonate reduces urine angiotensinogen and 
preserves glomerular filtration rate. Kidney Int 2014;86:1031–8.
 66. Bianchi S, Bigazzi R, Campese VM. Intensive versus conventional 
therapy to slow the progression of idiopathic glomerular diseases. 
Am J Kidney Dis 2010;55:671–81.
 67. Asselbergs FW, Diercks GFH, Hillege HL, et al. Effects of fosinopril 
and pravastatin on cardiovascular events in subjects with 
microalbuminuria. Circulation 2004;110:2809–16.
 68. Huskey J, Lindenfeld J, Cook T, et al. Effect of simvastatin on 
kidney function loss in patients with coronary heart disease: 
findings from the Scandinavian simvastatin survival study (4S). 
Atherosclerosis 2009;205:202–6.
 69. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of 
patients randomized in the Scandinavian simvastatin survival study 
(4S) of cholesterol lowering. Am J Cardiol 2000;86:257–62.
 70. Design and baseline results of the Scandinavian simvastatin survival 
study of patients with stable angina and/or previous myocardial 
infarction. Am J Cardiol 1993;71:393–400.
 71. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and 
stroke events with atorvastatin in hypertensive patients who have 
average or lower-than-average cholesterol concentrations, in the 
Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm 
(ASCOT-LLA): a multicentre randomised controlled trial. Lancet 
2003;361:1149–58.
 72. Gupta A, Chang CL, Collier D. 758 the relationship between 
statin therapy and progression of renal damage among 10305 
hypertensive patients randomised in the ASCOT-LIPID-LOWERING 
arm (LLA). 79th European Atherosclerosis Society Congress, EAS 
2011, Gothenburg Sweden, 2011:158–9.
 73. Nanayakkara PWB, van Guldener C, ter Wee PM, et al. Effect 
of a treatment strategy consisting of pravastatin, vitamin E, 
and homocysteine lowering on carotid intima-media thickness, 
endothelial function, and renal function in patients with mild to 
moderate chronic kidney disease: results from the anti-oxidant 
therapy in chronic renal insufficiency (ATIC) study. Arch Intern Med 
2007;167:1262–70.
 74. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in 
patients with chronic heart failure (the GISSI-HF trial): a randomised, 
double-blind, placebo-controlled trial. Lancet 2008;372:1231–9.
 75. Tavazzi L, Tognoni G, Franzosi MG, et al. Rationale and design 
of the GISSI heart failure trial: a large trial to assess the effects of 
n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic 
congestive heart failure. Eur J Heart Fail 2004;6:635–41.
 76. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin 
treatment on renal function and serum uric acid levels and their 
relation to vascular events in patients with coronary heart disease 
and metabolic syndrome: a subgroup analysis of the Greek 
atorvastatin and coronary heart disease evaluation (GREACE) study. 
Nephrol Dial Transplant 2007;22:118–27.
 77. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with 
atorvastatin to the National Cholesterol Educational Program goal 
versus ‘usual’ care in secondary coronary heart disease prevention. 
The GREek Atorvastatin and Coronary-heart-disease Evaluation 
(GREACE) study. Curr Med Res Opin 2002;18:220–8.
 78. Ford I, Bezlyak V, Stott DJ, et al. Reduced glomerular filtration rate 
and its association with clinical outcome in older patients at risk of 
vascular events: secondary analysis. PLoS Med 2009;6:e16.
 79. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed 
combination of perindopril and indapamide on macrovascular 
and microvascular outcomes in patients with type 2 diabetes 
mellitus (the advance trial): a randomised controlled trial. Lancet 
2007;370:829–40.
 80. Heerspink HJL, Ninomiya T, Perkovic V, et al. Effects of a fixed 
combination of perindopril and indapamide in patients with type 2 
diabetes and chronic kidney disease. Eur Heart J 2010;31:2888–96.
 81. Peters R, Beckett N, Poulter R, et al. Kidney function in the very 
elderly with hypertension: data from the hypertension in the very 
elderly (HYVET) trial. Age Ageing 2013;42:253–8.
 82. Beckett NS, Peters R, Fletcher AE, et al. Treatment of 
hypertension in patients 80 years of age or older. N Engl J Med 
2008;358:1887–98.
 83. Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the very 
elderly trial (HYVET): protocol for the main trial. Drugs Aging 
2001;18:151–64.
 84. Ting R-D, Keech AC, Drury PL, et al. Benefits and safety of long-
term fenofibrate therapy in people with type 2 diabetes and renal 
impairment: the field study. Diabetes Care 2012;35:218–25.
 85. FIELD Study Investigators. The need for a large-scale trial of fibrate 
therapy in diabetes: the rationale and design of the Fenofibrate 
Intervention and Event Lowering in Diabetes (FIELD) study. 
[ISRCTN64783481]. Cardiovasc Diabetol 2004;3:9.
 86. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate 
therapy on cardiovascular events in 9795 people with type 2 
diabetes mellitus (the field study): randomised controlled trial. 
Lancet 2005;366:1849–61.
 87. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, 
cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J 
Med 2015;373:2117–28.
 88. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and 
progression of kidney disease in type 2 diabetes. N Engl J Med 
2016;375:323–34.
 89. Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin 
on kidney function and respective cardiovascular outcomes 
in type 2 diabetes: outcomes from TECOS. Diabetes Care 
2016;39:2304–10.
 90. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin 
on cardiovascular outcomes in type 2 diabetes. N Engl J Med 
2015;373:232–42.
 91. Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients 
with systolic heart failure and mild symptoms. N Engl J Med 
2011;364:11–21.
 92. Rossignol P, Dobre D, McMurray JJV, et al. Incidence, determinants, 
and prognostic significance of hyperkalemia and worsening renal 
function in patients with heart failure receiving the mineralocorticoid 
receptor antagonist eplerenone or placebo in addition to optimal 
medical therapy: results from the eplerenone in mild patients 
hospitalization and survival study in heart failure (EMPHASIS-HF). 
Circ Heart Fail 2014;7:51–8.
 93. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on 
renal and cardiovascular outcomes in patients with type 2 diabetes 
and nephropathy. N Engl J Med 2001;345:861–9.
 94. de Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for 
renoprotection in patients with type 2 diabetic nephropathy: lessons 
from RENAAL. Kidney Int 2004;65:2309–20.
 95. Kowey PR, Dickson TZ, Zhang Z, et al. Losartan and end-
organ protection--lessons from the RENAAL study. Clin Cardiol 
2005;28:136–42.
 96. Winkelmayer WC, Zhang Z, Shahinfar S, et al. Efficacy and safety 
of angiotensin II receptor blockade in elderly patients with diabetes. 
Diabetes Care 2006;29:2210–7.
Protected by copyright.
 o
n
 O
ctober 21, 2019 at Barnes Library M
edical School.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030596 on 20 September 2019. Downloaded from 
12 Taylor KS, et al. BMJ Open 2019;9:e030596. doi:10.1136/bmjopen-2019-030596
Open access 
 97. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan 
renal protection study–rationale, study design and baseline 
characteristics of RENAAL (Reduction of Endpoints in NIDDM 
with the Angiotensin II Antagonist Losartan). J Renin Angiotensin 
Aldosterone Syst 2000;1:328–35.
 98. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for 
heart failure with preserved ejection fraction. N Engl J Med 
2014;370:1383–92.
 99. Crouse JR 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin 
on progression of carotid intima-media thickness in low-risk 
individuals with subclinical atherosclerosis: the METEOR trial. JAMA 
2007;297:1344–53.
 100. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a 
prospective study of pravastatin in the elderly at risk (prosper). 
PROSPER Study Group. prospective study of pravastatin in the 
elderly at risk. Am J Cardiol 1999;84:1192–7.
 101. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly 
individuals at risk of vascular disease (prosper): a randomised 
controlled trial. Lancet 2002;360:1623–30.
 102. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL 
cholesterol with simvastatin plus ezetimibe in patients with chronic 
kidney disease (study of heart and renal protection): a randomised 
placebo-controlled trial. Lancet 2011;377:2181–92.
 103. Haynes R, Lewis D, Emberson J, et al. Effects of lowering LDL 
cholesterol on progression of kidney disease. J Am Soc Nephrol 
2014;25:1825–33.
 104. Sharp Collaborative Group. Study of heart and renal protection 
(sharp): randomized trial to assess the effects of lowering low-
density lipoprotein cholesterol among 9,438 patients with chronic 
kidney disease. Am Heart J 2010;160:e10:785–94.
 105. Bode B, Stenlöf K, Harris S, et al. Long-term efficacy and safety of 
canagliflozin over 104 weeks in patients aged 55-80 years with type 
2 diabetes. Diabetes Obes Metab 2015;17:294–303.
 106. Bode B, Stenlöf K, Sullivan D, et al. Efficacy and safety of 
canagliflozin treatment in older subjects with type 2 diabetes 
mellitus: a randomized trial. Hosp Pract (1995) 2013;41:72–84.
 107. Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients 
with type 2 diabetes and moderate renal impairment shows that 
dapagliflozin reduces weight and blood pressure but does not 
improve glycemic control. Kidney Int 2014;85:962–71.
 108. Palmer SC, Navaneethan SD, Craig JC, et al. Hmg CoA reductase 
inhibitors (statins) for people with chronic kidney disease not 
requiring dialysis. Cochrane Database Syst Rev 2014;(5):CD007784.
 109. Zhang X, Xiang C, Zhou Y-H, et al. Effect of statins on 
cardiovascular events in patients with mild to moderate chronic 
kidney disease: a systematic review and meta-analysis of 
randomized clinical trials. BMC Cardiovasc Disord 2014;14:19.
 110. Herrington W, Emberson J, Mihaylova B, et al. Impact of renal 
function on the effects of LDL cholesterol lowering with statin-
based regimens: a meta-analysis of individual participant 
data from 28 randomised trials. Lancet Diabetes Endocrinol 
2016;4:829–39.
Protected by copyright.
 o
n
 O
ctober 21, 2019 at Barnes Library M
edical School.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-030596 on 20 September 2019. Downloaded from 
